Miltenyi Biotec Eyes Major India Market as It Develops Localized CAR-T Therapies
Loading more articles...
Miltenyi Biotec Boosts India's CAR-T Therapy: Made-for-India Solutions on the Horizon
M
Moneycontrol•20-02-2026, 12:11
Miltenyi Biotec Boosts India's CAR-T Therapy: Made-for-India Solutions on the Horizon
•Miltenyi Biotec, a German cell and gene therapy specialist, is expanding its presence in India beyond equipment supply to become a developer of home-grown CAR-T therapies.
•The company is collaborating with Christian Medical College (CMC) Vellore on a CD19-directed CAR-T program for blood cancers, with a Phase 1 trial showing safety and early efficacy in Indian patients.
•Miltenyi aims to make CAR-T therapy more affordable in India by enabling hospital-based manufacturing, reducing costs and turnaround times by eliminating complex central manufacturing and cold-chain logistics.
•The company emphasizes a "co-invented in Germany, made in India, for India" approach, with potential expansion beyond oncology to autoimmune diseases.
•Miltenyi is also preparing for European approval of Zamtocabtagene, a dual-target CAR-T therapy, which is expected to reach India, while prioritizing the acceleration of the Indian registration study for its CD19 therapy.
